Copy to clipboard 
The Board of Directors of Elos Medtech has agreed upon the timeline of the transition with current CEO Jan Wahlström’s tenure ending in connection with Elos Medtech’s Annual General Meeting on May 3, 2022.
While a search for Mr. Wahlström’s successor is underway, the Board appoints Jodie Gilmore, President & Business Unit Director Orthopedics, as interim Chief Executive Officer, and Søren Olesen, President & Business Unit Director Dental, as interim deputy Chief Executive Officer. Ms. Gilmore and Mr. Olesen will assume their positions in connection with Elos Medtech’s Annual General Meeting and will in parallel retain their current roles.
Both Gilmore and Olesen have over 30 years of experience in the industry and have successfully run their companies, which are now part of the Elos Group. In recent years, they have focused on strategic business development within each business area.
To ensure continuity during the transition period for the change of CEO, an Executive Committee has been appointed for Elos Medtech. This team comprises Jodie Gilmore, Søren Olesen and Ewa Linsäter, CFO. The committee has been appointed to maintain the company’s customer focus and growth, and thus continue in the same strategic direction during the transition period.
The appointment of Ms. Gilmore is conditional on the Swedish Companies Registration Office granting an exemption from the CEO’s residence requirement.
“We would again like to warmly thank Jan for his efforts as President and CEO of Elos Medtech and wish him all the best in the future,” said Lovisa Lander, Chairman of the Board.
Source: Elos Medtech
